Physician profile
Amy Layman
NPI 1215965454
$3,690.85
in general payments reported to CMS, 2019-2025
22 companies · $610 in 2025
The $610 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $309 · 2021: $381 · 2022: $743 · 2023: $451 · 2024: $612 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $754.14 | 2019-2025 | Clareon, Precision7, Total30 |
| Mallinckrodt Hospital Products INC. | $566.94 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $382.63 | 2022-2025 | Alden Scleral Zenlens, Xiidra |
| Sun Pharmaceutical Industries INC. | $229.96 | 2020-2021 | |
| Glaukos Corporation | $191.88 | 2022-2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Amgen INC. | $152.82 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $151.30 | 2021-2023 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.82 | 2019 | |
| Shire North American Group INC | $124.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
| Kala Pharmaceuticals, INC. | $121.85 | 2021 | |
| Biotissue Holdings INC. | $110.91 | 2019-2024 | |
| Johnson & Johnson Vision Care, INC. | $103.36 | 2023-2025 | Acuvue |
| Johnson & Johnson Surgical Vision, INC. | $96.19 | 2019 | |
| Abbvie INC. | $94.85 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $90.95 | 2024 | Dextenza |
| Staar Surgical Company | $77.23 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $49.39 | 2024 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $39.56 | 2025 | Eylea Hd |
| Coopervision INC. | $36.46 | 2019 | |
| Genentech USA, INC. | $34.63 | 2022 | |
| Dompe US, INC. | $28.00 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Layman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.